United States v. Oakland Cannabis Buyers' Cooperative

Background

In 1996, California voters passed Proposition 215, the Compassionate Use Act, allowing patients to use cannabis with a physician's recommendation ^[1]. The Oakland Cannabis Buyers' Cooperative (OCBC) was established to distribute cannabis to qualifying patients under the new state law ^[2].

In January 1998, the United States sued OCBC and several similar California dispensaries in federal court, seeking an injunction under the Controlled Substances Act (CSA), which prohibits the manufacture and distribution of Schedule I substances including cannabis ^[2][3]. The district court granted the injunction. OCBC kept operating, was held in contempt, and then asked the court to modify the injunction to allow distribution to patients with serious medical needs. The district court refused, but the Ninth Circuit reversed, ruling that 'medical necessity' was a legally cognizable defense ^[2]. The government appealed to the Supreme Court.

The Question Presented

The narrow legal question: does the Controlled Substances Act allow a 'medical necessity' exception to its prohibition on manufacturing and distributing cannabis? Strong evidence

The common-law necessity defense generally lets a defendant argue that breaking a law was justified to prevent a greater harm. The Ninth Circuit had held that for seriously ill patients with no legal alternative, distributing cannabis could fit this defense ^[2].

The Court's Holding

Justice Thomas, writing for the majority, held that there is no medical necessity exception to the CSA's prohibitions on manufacturing and distribution ^[2]. The reasoning, in short:

• Congress placed cannabis in Schedule I, which by statutory definition means the substance has 'no currently accepted medical use in treatment in the United States' (21 U.S.C. § 812(b)(1)(B)) ^[3].
• That legislative determination forecloses courts from finding a medical benefit sufficient to justify a necessity defense.
• The CSA's only explicit medical exception is for government-approved research — Congress knew how to write exceptions and chose not to write a broader one ^[2].

Justice Stevens, joined by Souter and Ginsburg, concurred only in the judgment. He agreed the cooperative could not invoke necessity here but argued the majority went too far in suggesting necessity could never apply to any CSA defendant, particularly individual patients rather than distributors ^[2]. Justice Breyer was recused because his brother, a district judge, had handled an earlier stage of the case ^[2].

What the Case Did and Did Not Decide

Decided: Federal courts cannot grant equitable relief allowing cannabis distribution on medical necessity grounds. The CSA's Schedule I classification controls ^[2].

Not decided: Whether state medical cannabis laws are preempted by federal law, whether individual patients (as opposed to distributors) could ever raise necessity, and whether the Commerce Clause permits federal regulation of purely intrastate medical cannabis. That last question went to the Court four years later in Gonzales v. Raich, which answered it in the federal government's favor ^[4]. Strong evidence

The OCBC decision did not strike down Proposition 215 or any state medical cannabis program. It simply confirmed that those state programs provide no defense in federal court.

Aftermath and Continuing Relevance

OCBC stopped distributing cannabis but continued operating as an advocacy and ID-card organization in Oakland ^[5].

The decision remains binding precedent. Federal prosecutors retain authority to charge cannabis offenses regardless of state law, though that authority has been constrained in practice by:

• The Rohrabacher-Farr amendment (now Rohrabacher-Blumenauer), a rider on annual appropriations bills since fiscal year 2015 that prohibits the Department of Justice from spending funds to prevent states from implementing medical cannabis laws ^[6]. The Ninth Circuit held in United States v. McIntosh (2016) that this bars federal prosecutions of people in substantial compliance with state medical cannabis law ^[7].
• DOJ enforcement priorities that, in practice, have largely de-emphasized prosecution of state-compliant operators — though formal guidance has shifted across administrations.

OCBC's core holding — that the CSA itself contains no medical exception — has not been overruled. If the DEA rescheduules cannabis (a process under active administrative consideration as of 2024-2025), the statutory basis Thomas relied on would change for that lower schedule, but OCBC's reasoning about Schedule I would remain intact for any substance still listed there. Strong evidence

Not Legal Advice

This article is informational and is not legal advice. Federal cannabis law is a moving target — appropriations riders, DEA scheduling actions, and DOJ enforcement memos can shift the practical landscape without overturning the underlying case law. If you have a specific legal question about cannabis activity, consult a licensed attorney in your jurisdiction.

Last verified: 2025. As of this date, United States v. Oakland Cannabis Buyers' Cooperative remains good law and cannabis remains a Schedule I substance under federal law, though an administrative rescheduling proposal to move it to Schedule III is pending.

Sources

How this page was made